NovoCure Ltd

NVCRNASDAQ · USD
16.00USD+0.17 (+1.08%)
569

NovoCure Ltd (NVCR) Covered Calls

As of September 28, 2026, NVCR has 21 covered call opportunities in the coming three months. Return ranges from 3.0 to 90.1% until expiration. Annualized return ranges from 9.9 to 540.6%. The nearest expiration is October 16, 2026. Maximum potential profit is $1,427.

Read more

Running NVCR covered calls helps you generate consistent income from NovoCure Ltd's shares you already own, turning a long stock position into a yield-producing asset. A covered call on NovoCure Ltd involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best NVCR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if NVCR stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling NVCR covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given NovoCure Ltd covered call is worth writing.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Income-focused investors, long-term NVCR holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling NVCR covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best NovoCure Ltd covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV percentile80.16% Elevated
  • Market cap (M$)1,843
  • 52 weeks high-26.20%
  • 52 weeks low61.20%
  • Analyst recommendationBuy
    1.86
  • Target price$27.14
    69.63% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.31
  • EPS growth next 5 years32.69%

As of September 28, 2026

2026-10-161820.0026.340.050.30422.0026.66540.57-0.32+0.13290.25
2026-10-161819.0020.030.050.60322.0020.34412.47-0.32+0.201000.55
2026-10-161818.0013.710.100.75227.0014.34290.78-0.63+0.272090.65
2027-03-1917230.0089.510.101.001427.0090.15191.30-0.63+0.1690.90
2026-10-161817.007.390.201.05137.008.65175.49-1.26+0.37740.85
2027-01-1510923.0045.290.100.90727.0045.93153.79-0.63+0.191,7270.80
2026-11-205318.0013.710.401.35257.0016.23111.81-2.53+0.3600.95
2027-03-1917224.0051.610.051.30822.0051.93110.19-0.32+0.227711.25
2027-01-1510920.0026.340.701.05487.0030.76103.02-4.42+0.312,1060.35
2026-11-205317.007.390.801.55197.0012.4485.70-5.05+0.45190.75

As of September 28, 2026

Sell covered calls with the data behind you

Find the best NVCR covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial